HuGE Literature Finder
Records
1
-
6
Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Oct . Pearson Alex, Proszek Paula Z, Pascual Javier, Fribbens Charlotte, Shamsher Monee K, Kingston Belinda, O'Leary Ben, Herrera-Abreu Maria Teresa, Cutts Rosalind J, Garcia-Murillas Isaac, Bye Hannah, Walker Brian A, Gonzalez De Castro David, Yuan Lina, Jamal Sabri, Hubank Michael, López-Knowles Elena, Schuster Eugene F, Dowsett Mitch, Osin Peter, Nerurkar Ashutosh, Parton Marina, Okines Alicia Fc, Johnston Stephen R D, Ring Alistair, Turner Nicholas |
Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer. Molecular cancer 2018 Feb 17 (1): 67. Takeshita Takashi, Yamamoto Yutaka, Yamamoto-Ibusuki Mutsuko, Tomiguchi Mai, Sueta Aiko, Murakami Keiichi, Iwase Hirota |
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. BMC cancer 2016 Nov 16 (1): 864. Ko Ryo, Kenmotsu Hirotsugu, Serizawa Masakuni, Koh Yasuhiro, Wakuda Kazushige, Ono Akira, Taira Tetsuhiko, Naito Tateaki, Murakami Haruyasu, Isaka Mitsuhiro, Endo Masahiro, Nakajima Takashi, Ohde Yasuhisa, Yamamoto Nobuyuki, Takahashi Kazuhisa, Takahashi Toshia |
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer 2016 Sep . Makker Vicky, Recio Fernando O, Ma Ling, Matulonis Ursula A, Lauchle Jennifer O, Parmar Hema, Gilbert Houston N, Ware Joseph A, Zhu Rui, Lu Shan, Huw Ling-Yuh, Wang Yulei, Koeppen Hartmut, Spoerke Jill M, Lackner Mark R, Aghajanian Carol |
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population. Asian Pacific journal of cancer prevention : APJCP 2012 13 (5): 2157-62. Xu Jia-Li, Wang Zhen-Wu, Hu Ling-Min, Yin Zhi-Qiang, Huang Ming-De, Hu Zhi-Bin, Shen Hong-Bing, Shu Yong-Qi |
PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung cancer (Amsterdam, Netherlands) 2011 Jan 71 (1): 82-8. Pu Xia, Hildebrandt Michelle A T, Lu Charles, Lin Jie, Stewart David J, Ye Yuanqing, Gu Jian, Spitz Margaret R, Wu Xife |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 28, 2022
- Content source: